STOCK TITAN
  1. Home
  2. Sec-filings
  3. AUTL
  4. [8-K] Autolus Therapeutics plc Reports Material Event

Autolus Therapeutics (NASDAQ: AUTL) passes all resolutions at 2026 AGM

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
8-K

Rhea-AI Filing Summary

Autolus Therapeutics plc reported the results of its 2026 Annual General Meeting held on June 29, 2026. Shareholders approved all six ordinary resolutions presented at the meeting.

They received and adopted the 2025 Annual Report and Accounts, with 165,846,326 votes for and 2,895,344 against. The directors’ remuneration report was approved with 156,192,216 votes for and 12,502,946 against. Ernst & Young LLP (US) was appointed as auditors, receiving 165,871,368 votes in favor and 2,872,225 against.

Shareholders also re-elected three directors. Mr. M Bonney was re-elected with 165,491,394 votes for and 3,312,126 against. Dr. E Leiderman was re-elected with 165,741,204 votes for and 3,063,838 against. Mr. R W Azelby was re-elected with 162,133,091 votes for and 6,671,776 against.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Accounts approval votes for 165,846,326 votes For adoption of 2025 Annual Report and Accounts
Accounts approval votes against 2,895,344 votes Against adoption of 2025 Annual Report and Accounts
Remuneration report votes for 156,192,216 votes For directors’ remuneration report
Remuneration report votes against 12,502,946 votes Against directors’ remuneration report
Auditor appointment votes for 165,871,368 votes For appointment of Ernst & Young LLP (US)
M Bonney re-election votes for 165,491,394 votes For re-election as director
E Leiderman re-election votes for 165,741,204 votes For re-election as director
R W Azelby re-election votes for 162,133,091 votes For re-election as director
Annual General Meeting financial
"held its 2026 Annual General Meeting of Shareholders (the “AGM”)."
remuneration report financial
"To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy)"
A remuneration report is a formal disclosure that lists how much company leaders and board members are paid, including salaries, bonuses, stock awards, pension and other benefits, and explains the rules used to set that pay. Investors use it like a receipt or scorecard to judge whether management’s incentives are aligned with shareholder interests, to estimate ongoing costs, and to spot governance or risk issues that could affect a stock’s value.
auditors’ remuneration financial
"and to authorize the Directors to determine the auditors’ remuneration."
ordinary resolutions financial
"Ordinary Resolutions Resolution 1: To receive and adopt the Company’s accounts"
An ordinary resolution is a decision put to a company’s shareholders that is approved by a simple majority of votes cast, similar to a club decision passed when more than half the members agree. It covers routine matters such as electing directors, approving annual accounts or declaring dividends, and matters approved this way bind the company. Investors care because ordinary resolutions determine everyday governance and can change leadership, financial distributions, or policies with only majority support.
abstention financial
"An abstention is not a vote in law and is not counted"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001730463FALSE00017304632026-06-292026-06-290001730463sic:Z88802026-06-292026-06-290001730463us-gaap:CommonClassAMember2026-06-292026-06-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2026
Autolus Therapeutics plc
(Exact name of registrant as specified in its Charter)

England and Wales
001-38547
Not applicable
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
The Mediaworks
191 Wood Lane
LondonW12 7FP
United Kingdom
(Address of principal executive offices)(Zip Code)
(44) 20
3829 6230
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share
AUTLThe Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share**
The Nasdaq Stock Market LLC*
*
Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 29, 2026, Autolus Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the six resolutions set forth below, each of which were voted on and duly passed on a poll at the AGM. Each resolution is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 5, 2026 (the “Proxy Statement”). Set forth below are the results, including the number of votes cast for, against and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution.
Ordinary Resolutions
Resolution 1: To receive and adopt the Company’s accounts for the financial year ended 31 December 2025 and the associated reports of the Directors and auditors (the “2025 Annual Report and Accounts”). The votes were cast as follows:
ForAgainstAbstain
165,846,3262,895,34475,901
Resolution 2: To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy), as set out on pages 38 to 67 of the 2025 Annual Report and Accounts. The votes were cast as follows:
ForAgainstAbstain
156,192,21612,502,946122,409
Resolution 3: To appoint Ernst & Young LLP (US) as auditors of the Company to hold office from the conclusion of the 2026 AGM until the conclusion of the 2027 AGM and to authorize the Directors to determine the auditors’ remuneration. The votes were cast as follows:
ForAgainstAbstain
165,871,3682,872,22573,978



Resolution 4: To re-elect Mr. M Bonney as a Director. The votes were cast as follows:
ForAgainstAbstain
165,491,3943,312,12614,051
Resolution 5: To re-elect Dr. E Leiderman as a Director. The votes were cast as follows:
ForAgainstAbstain
165,741,2043,063,83812,529
Resolution 6: To re-elect Mr. RW Azelby as a Director. The votes were cast as follows:
ForAgainstAbstain
162,133,0916,671,77612,704
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AUTOLUS THERAPEUTICS PLC
Dated: June 29, 2025By:/s/Christian Itin, Ph.D.
Name: Christian Itin, Ph.D.
Title: Chief Executive Officer



Source: View Original Filing on SEC EDGAR

FAQ

What did Autolus Therapeutics (AUTL) shareholders approve at the 2026 AGM?

Shareholders approved all six ordinary resolutions, including the 2025 Annual Report and Accounts, the directors’ remuneration report, the appointment of Ernst & Young LLP (US) as auditors, and the re-election of three directors.

How did Autolus Therapeutics (AUTL) vote on the 2025 Annual Report and Accounts?

The 2025 Annual Report and Accounts were adopted with 165,846,326 votes for and 2,895,344 against. There were 75,901 abstentions, which are not counted in the proportion of votes for or against the resolution.

What were the results for the directors’ remuneration report at Autolus Therapeutics’ 2026 AGM?

The directors’ remuneration report was approved with 156,192,216 votes for and 12,502,946 against. There were 122,409 abstentions, which do not count toward the for-or-against vote calculation under the company’s voting rules.

Which auditors did Autolus Therapeutics (AUTL) appoint at the 2026 AGM and for what period?

Shareholders appointed Ernst & Young LLP (US) as auditors from the conclusion of the 2026 AGM until the conclusion of the 2027 AGM, with 165,871,368 votes in favor, 2,872,225 against, and 73,978 abstentions.

Which directors of Autolus Therapeutics were re-elected at the 2026 AGM?

Shareholders re-elected three directors: Mr. M Bonney, Dr. E Leiderman, and Mr. R W Azelby. Each received a strong majority of votes in favor, with separate resolutions and vote tallies recorded for each director.

How strong was support for director R W Azelby at Autolus Therapeutics’ 2026 AGM?

Mr. R W Azelby was re-elected with 162,133,091 votes for and 6,671,776 against. There were 12,704 abstentions, which are not counted when calculating the proportion of votes for or against his re-election resolution.

Filing Exhibits & Attachments

4 documents

Other Documents